Evidence map›Paper›PMID 32289532›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2021

Delay in Retreatment of Helicobacter pylori Infection Increases Risk of Upper Gastrointestinal Bleeding.

Chuan-Guo Guo, Ka Shing Cheung, Feifei Zhang, Esther W Chan, Lijia Chen, Ian C K Wong, Wai K Leung

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Quality indicators for upper GI endoscopy.Gastrointestinal endoscopy · 2025
    Guideline
  2. Risk ofGastro hep advances · 2026
    Article
  3. Article
  4. Observational
  5. Quality Indicators for Upper GI Endoscopy.The American journal of gastroenterology · 2025
    Article
  6. Article
  7. Article
  8. Antibiotic Resistance, Susceptibility Testing and Stewardship inInternational journal of molecular sciences · 2023
    Review
  9. Detection and Treatment ofGastroenterology research and practice · 2022
    Review
  10. Role ofExperimental and therapeutic medicine · 2021
    Article
  11. Diagnosis ofDiagnostics (Basel, Switzerland) · 2021
    Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Chuan-Guo GuoDepartment of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Ka Shing CheungDepartment of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Feifei ZhangUsher Institute, University of Edinburgh, Edinburgh, United Kingdom.
Esther W ChanCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, China.
Lijia ChenDepartment of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Ian C K WongCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, China; Research Department of Practice and Policy, UCL School of Pharmacy, University College London, London, United Kingdom.
Wai K LeungDepartment of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China. Electronic address: waikleung@hku.hk.
University of Hong Kong · HKHKU-Pasteur Research Pole · HKUniversity College London · GBUniversity of Edinburgh · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsLittle is known about risk of upper gastrointestinal bleeding (UGIB) in patients failed by Helicobacter pylori eradication therapy. We investigated the effects of different time until retreatment, after failure of initial H pylori eradication therapy, on subsequent risk of UGIB.

methodsWe performed a territory-wide retrospective cohort study of 70,518 patients with H pylori infection who had received their first course of clarithromycin-based triple therapy from January 2003 through December 2012 in Hong Kong. Patients who required retreatment after failed initial therapy (n = 8330, 11.8%) were categorized based on time between initial and final H pylori eradication (3 months or less, 3-12 months, and more than 12 months). We collected clinical data from 30 days after prescription of the last course of H pylori therapy until hospitalization for non-variceal UGIB, death, or the end of the study (30 Jun 2016; median follow-up time, 7.65 years). The primary outcome was difference in development UGIB (determined from ICD-9 codes) between patients who required retreatment and those who did not (reference group).

resultsCompared with the reference group, patients who required retreatment had an overall higher risk of UGIB, even after last eradication therapy (adjusted hazard ratio (HR), 1.50, 95% CI, 1.34-1.69). There was a progressive increase in risk of UGIB with longer time from initial until final eradication therapy: hazard ratio for time less than 3 months, 1.16; 95% CI, 0.88-1.54, hazard ratio for time 3-12 months, 1.35; 95% CI, 1.07-1.69, and hazard ratio for time more than 12 months, 1.68; 95% CI, 1.46-1.94 (P for trend = .038).

conclusionIn a retrospective study of patients in Hong Kong, we found that those failed by initial H pylori eradication have an increased risk of UGIB, compared to patients who responded to the initial therapy. Risk increased progressively with longer time until retreatment. Early retreatment within 3 months should be considered to minimize subsequent UGIB risk.

Indexed as

Helicobacter InfectionsHelicobacter pyloriAnti-Bacterial AgentsDrug Therapy, CombinationGastrointestinal HemorrhageHumansRetreatmentRetrospective StudiesAnti-Bacterial AgentsLatency IntervalPeptic UlcerPreventionStomach

Identifiers

PMID32289532
OpenAlexW3015520859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.